⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20395920 | 0.99 | — | — | |
| SCHEMBL252711 | 0.87 | — | — | |
| SCHEMBL723880 | 0.82 | — | — | |
| SCHEMBL2568072 | 0.79 | CYP1A2 (0.38) | — | |
| SCHEMBL34280 | 0.79 | CYP1A2 (0.38) | — | |
| Hydrochloric Acid SCHEMBL153625 | 0.78 | CYP1A2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL1071947 | 0.78 | CYP1A2 (0.36) | — | |
| SCHEMBL21808585 | 0.78 | CYP1A2 (0.36) | — | |
| Hydrochloric Acid SCHEMBL5078995 | 0.78 | CYP1A2 (0.36) | — | |
| Iodomethane SCHEMBL898632 | 0.76 | CYP1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4215206-A1 | PROTEIN COMPRISING NC-1 FOR TREATING ANGIOGENESIS-RELATED DISEASES | Deutsches Krebsforschungszentrum (DE) | 2023-07-26 | — | — | EP | disclosed |
| EP-3253417-B1 | ENGINEERED TISSUE SUBSTITUTE SYSTEM | UNIV BRITISH COLUMBIA (CA) | 2023-06-21 | — | — | EP | disclosed |
| EP-2747775-B1 | PROTEIN COMPRISING NC-1 FOR TREATING ANGIOGENESIS-RELATED DISEASES | DEUTSCHES KREBSFORSCH (DE) | 2023-03-22 | — | — | EP | disclosed |
| US-11359000-B2 | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-10865811-B2 | Engineered tissue substitute system | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-12-15 | — | — | US | disclosed |
| US-10787494-B2 | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-29 | — | — | US | disclosed |
| US-10767037-B2 | Hyaluronic acid conjugates and uses thereof | UNIVERSITE DE GENEVE (CH) | 2020-09-08 | — | — | US | disclosed |
| US-20200087603-A1 | BIOREACTOR MODULE, A BIOREACTOR SYSTEM AND METHODS FOR THICK TISSUE SEEDING AND CULTIVATION IN AN HIERARCHICAL ORGANIZATION AND PHYSIOLOGICAL MIMICKING CONDITIONS | UNIV NANYANG TECH (SG) | 2020-03-19 | — | — | US | disclosed |
| US-20190300592-A1 | INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3495505-A1 | QUANTITATIVE ASSESSMENT FOR CAP EFFICIENCY OF MESSENGER RNA | Translate Bio, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20060234285-A1 | For treating or preventing inflammatory diseases, autoimmune diseases, graft versus host disease (GVHD), allergis, asthma, and/or hepatitis; drug screening | HUMAN GENOME SCIENCES, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1322667-A4 | TUMOR NECROSIS FACTOR RECEPTORS 6-ALPHA AND 6-BETA | HUMAN GENOME SCIENCES INC (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040013664-A1 | Antiinflamamtory agents; antiallergens; antihistamines | HUMAN GENOME SCIENCES, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030198640-A1 | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta | HUMAN GENOME SCIENCES, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2002064612-A9 | HUMAN G-PROTEIN CHEMOKINE RECEPTOR (CCR5) HDGNR10 | HUMAN GENOME SCIENCES INC (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030170203-A1 | Death domain containing receptors | HUMAN GENOME SCIENCES, INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030129189-A1 | Angiogenesis inhibitors for treament of inflammation, cachexia, septic shock, cerebral malaria, arthritis, and graft-rejection | HUMAN GENOME SCIENCES, INC. | 2003-07-10 | — | — | US | disclosed |
| EP-1322667-A2 | TUMOR NECROSIS FACTOR RECEPTORS 6-ALPHA AND 6-BETA | HUMAN GENOME SCIENCES, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020150583-A1 | Antiinflammatory agents | HUMAN GENOME SCIENCES, INC. (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002018622-A2 | TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b) | HUMAN GENOME SCIENCES, INC. (US) | 2002-03-07 | — | — | WO | disclosed |